ArticleThe World Allergy Organization journal2026
Rhizoma Dioscoreae Nipponicae attenuates airway remodeling and angiogenesis-related changes in asthma with altered mTOR/4EBP1/HIF-1α/VEGF pathway markers.
Article in The World Allergy Organization journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Asthma is a chronic inflammatory airway disease characterized by airway remodeling and hyperresponsiveness. Angiogenesis is a key contributor to airway remodeling and disease progression. Rhizoma Dioscoreae Nipponicae (RDN), a traditional Chinese medicine, has shown anti-inflammatory and anti-angiogenic potential, but its effects on asthma-associated airway remodeling remain unclear. Methods: The chemical profile of the RDN extract was characterized using UHPLC-Q Exactive Orbitrap MS/MS. An ovalbumen-induced mouse model of asthma and C166 mouse endothelial cells were used to examine the effects of RDN treatment. Histopathological changes were assessed using H&E and Masson's trichrome staining. mRNA and protein expression levels of key components in the mTOR/4EBP1/HIF-1α/VEGF signaling pathway were analyzed by qPCR and Western blot. Results: UHPLC-Q Exactive Orbitrap MS/MS analysis tentatively annotated 2509 constituents and demonstrated good batch-to-batch chemical consistency of the RDN extract. Compared with the model group, RDN treatment significantly reduced the airway inflammation score by approximately 39.5% ( Conclusion: RDN alleviated airway inflammation and remodeling at the histopathological level, and these effects were associated with downregulation of markers within the mTOR/4EBP1/HIF-1α/VEGF pathway. These findings suggest that RDN may be a promising therapeutic agent for ameliorating airway remodeling in asthma. Future studies incorporating analyses of phosphorylation states are warranted to further clarify the underlying mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.